Articles tagged "HLA antibodies"

2019 American Transplant Congress
Nivolumab-Induced Rejection of a Liver Allograft: PD-1 Inhibition Thwarts Liver Allograft Resistance to Humoral Rejection
B. T. Lee, H. Han, S. Chopra, A. J. Ahearn
Surgery, USC Keck School of Medicine, Los Angeles, CA
*Purpose: Checkpoint inhibitor therapy with Programmed cell death protein (PD-1) inhibitors has recently been FDA approved for the treatment of several malignancies. However, it has…
2019 American Transplant Congress
Kinetics of Pretransplant DSA, Post-Transplant Histology, and Graft Failure after Kidney Transplantation
A. Senev¹, E. Lerut², V. Van Sandt³, J. Callemeyn¹, M. Coemans¹, B. Sprangers², D. Kuypers², M. Emonds¹, M. Naesens²
¹Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium, ²University Hospitals Leuven, Leuven, Belgium, ³Histocompatibility and Immunogenetics Laboratory, Belgian Red Cross-Flanders, Mechelen, Belgium
*Purpose: The association between the kinetics of pretransplant DSA levels and outcome after kidney transplantation is currently not well known. In this large cohort study…
2019 American Transplant Congress
In Vitro Model for Detection of HLA Antibodies from Long Lived Plasma Cells
M. Merzkani¹, N. Moore¹, X. Benavides¹, B. Smith¹, W. Park¹, A. Bentall¹, K. Medina², M. Gandhi³, M. Stegall¹
¹Transplant, Mayo Clinic, Rochester, MN, ²Immunology, Mayo Clinic, Rochester, MN, ³Transfusion Medicine, Mayo Clinic, Rochester, MN
*Purpose: One of the major causes of kidney allograft loss is antibody mediated rejection. This process is mainly mediated by HLA antibodies(Abs) which are believed…
2019 American Transplant Congress
“Desens Light”: Single Center Experience Using Rituximab for High Immunologic Risk Kidney Transplant Recipients with Historic DSA
A. Casillas-Abundis, A. Tambur, A. Shetty, C. D'Agostino, J. R. Leventhal
Comprehensive Transplant Center, Northwestern Memorial Hospital, Chicago, IL
*Purpose: To evaluate the effectiveness of rituximab as induction therapy for pts undergoing kidney transplant (Tx) with historic DSA (hDSA) [Desens. Light].*Methods: 104 consecutive pts…
2019 American Transplant Congress
Immunologic Impact Of Native Kidney Function On Liver Transplant Patients
M. Mujtaba, S. Merwat, J. Fair, M. Bilal, A. Chatila, R. Kulkarni, J. Zou, S. Hussain, A. Gamilla-Crudo
Univ. of Texas Medical Branch, Galveston, TX
*Purpose: Renal failure in the setting of liver transplantation (LTx) is common and has an adverse impact on short and long-term graft and patient survival.…
2019 American Transplant Congress
Mismatched Epitope and De Novo DSA Development: An Analysis of the Benefit and Benefit-EXT Renal Transplant Cohorts
V. Jucaud¹, V. Burnett¹, H. Gebel², R. Bray², M. Polinsky³, M. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²Emory University, Atlanta, GA, ³Bristol-Myers Squibb, Princeton, NJ
*Purpose: De novo donor-specific HLA antibodies (dnDSA) target epitopes rather than whole antigens, and their development is associated with the mismatched HLA antibody epitope load…
2019 American Transplant Congress
Clazakizumab Acts on Endothelial Cells to Limit Antibody Mediated Damage
J. Lion¹, K. Poussin¹, E. Chong², D. Glotz³, N. A. Mooney¹
¹Alloimmunité-Autoimmunité-Transplantation, INSERM, Paris, France, ²Vitaeris, Vancouver, BC, Canada, ³Nephrology and Transplantation, Hôpital Saint Louis, Paris, France
*Purpose: Human microvascular endothelial cell expression of HLA class II antigens is strongly increased, both in vitro and in vivo, under inflammatory conditions. HLA class…
2019 American Transplant Congress
Efficacy Of Rituximab Monotherapy On Anti-human Leukocyte Antigen Antibodies In Highly Sensitized Living Donor Kidney Transplant Patients.
D. J. Sindi¹, A. Al Jedai², H. Aleid³, J. Brockmann⁴, M. Al-Awwami⁵, D. Alissa², E. De Vol⁶, H. Al Khabbaz⁷, L. Fajji⁸
¹Clinical Pharmacy, King Faisal Specialist Hospital and Research Center (KFSH&RC), Riyadh, Saudi Arabia, ²Clinical Pharmacy, KFSH&RC, Riyadh, Saudi Arabia, ³Kidney and Pancreas transplantation, KFSH&RC, Riyadh, Saudi Arabia, ⁴kFSH&RC, Riyadh, Saudi Arabia, ⁵Clinical Director, Histocompatibility and Immunogenetics Laboratory, KFSH&RC, Riyadh, Saudi Arabia, ⁶KFSH&RC, Riyadh, Saudi Arabia, ⁷Riyadh Elm University, Riyadh, Saudi Arabia, ⁸Clinical Transplant Coordinator, KFSH&RC, Riyadh, Saudi Arabia
*Purpose: We aim to examine the efficacy of Rituximab (RTX) monotherapy in reducing DSA in Highly Sensitised Living Donor Kidney Transplant (HS-LDKT) candidates and potentially…
2019 American Transplant Congress
Mismatched Antibody Epitopes and the Development of HLA-DQ De Novo DSA during Immunosuppression Withdrawal in Liver Transplant Recipients
V. Jucaud¹, A. Shaked², M. DesMarais³, P. Sayre⁴, S. Feng⁴, J. Levitsky⁵, M. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²University of Pennsylvania, Philadelphia, PA, ³Immune Tolerance Network, San Francisco, CA, ⁴University of California San Francisco, San Francisco, CA, ⁵Northern Western University, Chicago, IL
*Purpose: We recently described, in liver transplant (LT) recipients from the ITN030ST study, the development of de novo donor-specific HLA antibodies (dnDSA) and their impact…
2019 American Transplant Congress
Successful Kidney Transplantation of Highly Sensitized Candidates across Positive Cross Match and Strong Donor-Specific HLA-DP Antibodies without Desensitization
R. Rajalingam¹, D. D. Gae², Z. G. Laszik³, M. M. Tavakol⁴, A. B. Webber⁵, K. Cunniffe², G. da Gente², R. Hirose⁴, G. Roll⁴, C. E. Freise⁴, J. P. Roberts⁴
¹Immunogenetics and Transplantation Laboratory (ITL), San Francisco, CA, ²Department of Surgery, Immunogenetics and Transplantation Laboratory (ITL), San Francisco, CA, ³Department of Pathology, University of California San Francisco, San Francisco, CA, ⁴Department of Surgery, University of California San Francisco, San Francisco, CA, ⁵Department of Medicine, University of California San Francisco, San Francisco, CA
*Purpose: Over 50% of kidney transplant (Ktx) candidates with 100% CPRA display HLA-DP antibodies, which impair the chances of finding a compatible deceased donor (DD)…